this could go as low as $10-$13 in the near term esp if zyprexa battle fails.
AMVaz was the biggest disappointment for me. the only explanation is pfizer's legal counsel and the judges in the appellate court are golf-buddies. the text in the legal statute was so much in favor of reddy's. but alas....as much as i would like to think that the US legal system is fair and mature...there is still that 5-10% of corruption.
again this is a fantastic company. but in the near future there are no exciting products. zyprexa if they win the court battle can give them some growth in 2004-2005.
i like the way the company is trying to align itself. IMO this will be the first indian company to have it's name on a new drug. when that happens....that's a great thing for RDY and an equally great thing for india.